首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

2078317

人類微生物組市場：依產品類型、應用、適應症、通路和地區分類

Human Microbiome Market, By Product Type, By Application, By Disease Indication, By Distribution Channel, and By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，人類微生物組市場規模將在 2026 年達到 11.973 億美元，預計到 2033 年將達到 56.457 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 24.8%。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	11.973億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	24.80%	預計金額（2033 年）	56.457億美元

根據美國國家生物技術資訊中心（NCBI）的數據，每個人體內都存在10兆到100兆個共生微生物細胞，其中絕大多數是腸道細菌。人類微生物組則是由這些微生物細胞所包含的基因集所構成。世界各地已推出了多項與微生物組相關的研究項目，旨在闡明這些微生物的作用及其對人類健康的影響。這些研究正致力於探索其在肥胖症、糖尿病、自體免疫疾病、癌症、胃腸道疾病和中樞神經系統疾病等疾病治療的潛在應用。

市場動態

預計在預測期內，各種腸道疾病（例如發炎性腸道疾病 (IBD) 和克隆氏症）盛行率的不斷上升將加速全球人類微生物組市場的成長。例如，根據2019年10月發表在《採血針》上的一項研究，美國克隆氏症的報告病例數約為每10萬人319例，歐洲約為每10萬人322例。根據美國疾病管制與預防中心 (CDC) 2018年的統計數據，2015年美國約有1.3%（300萬人）的成年人被診斷出患有IBD（克隆氏症或潰瘍性大腸炎）。與1999年相比，IBD的盛行率顯著上升，當時美國成年人的IBD盛行率為0.9%（200萬人）。

市場參與企業正積極進行非有機成長活動，例如研發合作，預計將進一步加速預測期內的市場成長。例如，2017年，Second Genome公司與史丹佛癌症研究所、海德堡大學、羅斯威爾帕克綜合癌症中心和約翰·圖勒癌症中心等研究機構合作，評估腸道菌叢對個別癌症免疫療法反應的影響。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本節根據公司概況、產品系列、主要趨勢、財務表現和策略等各種參數，對全球人類微生物組市場的主要公司進行介紹。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
《全球人類微生物組市場》報告面向該行業的眾多相關人員，包括投資者、供應商、製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過分析全球人類微生物組市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

公司簡介
- Seres Therapeutics
- BIOMESENSE
- Microbiotica
- Vedanta Biosciences, Inc.
- SECOND GENOME THERAPEUTICS
- Finch Therapeutics Group, Inc
- Enterome
- BiomX
- MaaT Pharma
- Azitra
- Illumina, Inc
- Locus Biosciences, Inc
- Finch Therapeutics Group, Inc
- Rebiotix Inc
- Servatus Ltd
- Microbiome Research Pvt. Ltd
- AOBiome
- Axial Therapeutics, Inc
- Biomica

第10章

參考
分析方法

簡介目錄

Product Code: CMI182

Human Microbiome Market is estimated to be valued at USD 1,197.3 Mn in 2026 and is expected to reach USD 5,645.7 Mn by 2033, growing at a compound annual growth rate (CAGR) of 24.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,197.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	24.80%	2033 Value Projection:	USD 5,645.7 Mn

According to the National Center for Biotechnology (NCBI), the human microbiota consists of 10-100 trillion symbiotic microbial cells, which is harbored by each person, this primarily includes bacteria in the gut. The human microbiome consists of the genes these microbial cells harbor. Microbiome projects worldwide have been launched with the goal of understanding the roles that these microbes play and their impacts on human health. They are being studied for the treatment of diseases such as obesity, diabetes, autoimmune disorders, cancer, gastrointestinal disorders, central nervous system disorders, and others.

Market Dynamics

Increasing incidence rate of various gut disorders (inflammatory bowel disease (IBD), Crohn's disease etc.) is expected to increase the growth of the global human microbiome market over the forecast period. For instance, according to a study published in Lancet in October 2019, around 319 (U.S.) cases and around 322 (Europe) cases of Crohn's disease were reported per 100,000 people. As per the Centers for Disease Control and Prevention's (CDC) 2018 statistics, an estimated 1.3% of the U.S. adults (accounting for 3 million individuals) were diagnosed with IBD (either Crohn's disease or ulcerative colitis) in 2015. This showcased a major increase in the incidence rate of IBD from 1999, when 0.9% of the U.S. adults (2 million) were diagnosed with IBD.

Market players are involved in inorganic activities such as collaborations for research and development activities. This is expected to increase the growth of the market over the forecast period. For instance, in 2017, Second Genome, Inc., collaborated with the research institutes i.e., Stanford Cancer Institute, Ruprecht-Karl's-University Heidelberg, Roswell Park Comprehensive Cancer Center, and John Theurer Cancer Center in order to evaluate the effect of gut microbiota on individual response to cancer immunotherapies.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global human microbiome market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include ENTEROME SA, Embion Technologies S.A, IGEN BIOLAB GROUP, Evelo Biosciences Inc., Ferring Pharmaceuticals, 4D Pharma Plc., Gnubiotics Sciences, YSOPIA Bioscience, ViThera Pharmaceuticals Inc., SECOND GENOME THERAPEUTICS, Osel Inc., OxThera AB, Immuron Ltd., AOBiome, Vedanta Biosciences, Inc., Rebiotix Inc., Seres Therapeutics, Inc., Assembly Biosciences, Inc., and Finch Therapeutics Group, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global human microbiome market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the human microbiome market

Detailed Segmentation:

Global Human Microbiome Market, By Product Type (Revenue, USD Mn, 2021 - 2033)
Foods
Probiotics
Prebiotics
Medical Foods
Fecal Microbiota Transplant (FMT)
Microbiome Drugs
Others
Global Human Microbiome Market, By Disease Indication (Revenue, USD Mn, 2021 - 2033)
Clostridium Difficile Infection (CDI)
Inflammatory Bowel Disease (IBD)
Metabolic Disorders
Autoimmune Disorders
Allergic Diseases
Others
Global Human Microbiome Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Human Microbiome Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.S.
  - Canada
Latin America
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - U.K.
  - Germany
  - Italy
  - Spain
  - France
  - Russia
  - Rest of Europe
Asia Pacific
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - Australia
  - India
  - China
  - Japan
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
Middle East
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country:
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Product Type:
  - Foods
  - Fecal Microbiota Transplant (FMT)
  - Microbiome Drugs
  - Others
- By Disease Indication:
  - Clostridium Difficile Infection (CDI)
  - Inflammatory Bowel Disease (IBD)
  - Metabolic Disorders
  - Autoimmune Disorders
  - Allergic Diseases
  - Others
- By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
- By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
ENTEROME SA*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
Embion Technologies S.A
IGEN BIOLAB GROUP
Evelo Biosciences Inc
Ferring Pharmaceuticals
4D Pharma Plc
Gnubiotics Sciences
YSOPIA Bioscience
ViThera Pharmaceuticals Inc.
SECOND GENOME THERAPEUTICS
Osel Inc.
OxThera AB
Immuron Ltd.
AOBiome
Vedanta Biosciences, Inc.
Rebiotix Inc.
Seres Therapeutics, Inc.
Assembly Biosciences, Inc.
Finch Therapeutics Group, Inc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Human Microbiome Market, By Product Type, 2021- 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Food
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
  - Probiotics
  - Prebiotics
  - Medical Food Supplements
Microbiome Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Fecal Microbiota Transplant
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others (Symbiotic, Antibiotics, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

5. Global Human Microbiome Market, By Application, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Nutrition and Deities
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

6. Global Human Microbiome Market, By Disease Indication, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Auto Immune Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Clostridium Difficile Infection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Metabolic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Inflammatory Bowel Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Infectious Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends
Others (Cancer, Rare Diseases)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Segment Trends

7. Global Human Microbiome Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)

8. Global Human Microbiome Market, By Region, 2021 - 2033, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 - 2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2021 -2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021-2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 -2033, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Seres Therapeutics
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- BIOMESENSE
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Microbiotica
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Vedanta Biosciences, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- SECOND GENOME THERAPEUTICS
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Finch Therapeutics Group, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Enterome
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- BiomX
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- MaaT Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Azitra
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Illumina, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Locus Biosciences, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Finch Therapeutics Group, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Rebiotix Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Servatus Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Microbiome Research Pvt. Ltd
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AOBiome
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Axial Therapeutics, Inc
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Biomica
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies